FBIO Quote, Financials, Valuation and Earnings

Checkpoint Therapeutics has a net margin of -87.96% compared to Fortress Biotech's net margin of -16268.29%. Fortress Biotech's return on equity of -- beat Checkpoint Therapeutics's return on equity of --.

Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 950.23%. On the other hand Checkpoint Therapeutics has an analysts' consensus of $4.33 which suggests that it could grow by 8.61%. Given that Fortress Biotech has higher upside potential than Checkpoint Therapeutics, analysts believe Fortress Biotech is more attractive than Checkpoint Therapeutics.

Fortress Biotech has a beta of 1.825, which suggesting that the stock is 82.547% more volatile than S&P 500. In comparison Checkpoint Therapeutics has a beta of 1.211, suggesting its more volatile than the S&P 500 by 21.135%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Checkpoint Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Checkpoint Therapeutics pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $14.6M, which are larger than Checkpoint Therapeutics quarterly revenues of $41K. Fortress Biotech's net income of -$12.9M is lower than Checkpoint Therapeutics's net income of -$9.7M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Checkpoint Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.41x versus -- for Checkpoint Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Journey Medical has a net margin of -87.96% compared to Fortress Biotech's net margin of 11.17%. Fortress Biotech's return on equity of -- beat Journey Medical's return on equity of -97.05%.

Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 950.23%. On the other hand Journey Medical has an analysts' consensus of $9.88 which suggests that it could grow by 63.77%. Given that Fortress Biotech has higher upside potential than Journey Medical, analysts believe Fortress Biotech is more attractive than Journey Medical.

Fortress Biotech has a beta of 1.825, which suggesting that the stock is 82.547% more volatile than S&P 500. In comparison Journey Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Journey Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Journey Medical pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $14.6M, which are larger than Journey Medical quarterly revenues of $13.6M. Fortress Biotech's net income of -$12.9M is lower than Journey Medical's net income of $1.5M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Journey Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.41x versus 2.19x for Journey Medical. Usually stocks with elevated PS ratios are considered overvalued.

Durect has a net margin of -87.96% compared to Fortress Biotech's net margin of -222.37%. Fortress Biotech's return on equity of -- beat Durect's return on equity of -195.11%.

Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 950.23%. On the other hand Durect has an analysts' consensus of $6.75 which suggests that it could grow by 801.2%. Given that Fortress Biotech has higher upside potential than Durect, analysts believe Fortress Biotech is more attractive than Durect.

Fortress Biotech has a beta of 1.825, which suggesting that the stock is 82.547% more volatile than S&P 500. In comparison Durect has a beta of 0.883, suggesting its less volatile than the S&P 500 by 11.665%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Durect offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Durect pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $14.6M, which are larger than Durect quarterly revenues of $1.9M. Fortress Biotech's net income of -$12.9M is lower than Durect's net income of -$4.3M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Durect's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.41x versus 11.41x for Durect. Usually stocks with elevated PS ratios are considered overvalued.

Mustang Bio has a net margin of -87.96% compared to Fortress Biotech's net margin of --. Fortress Biotech's return on equity of -- beat Mustang Bio's return on equity of --.

Fortress Biotech has a consensus price target of $15.33, signalling upside risk potential of 950.23%. On the other hand Mustang Bio has an analysts' consensus of -- which suggests that it could grow by 7094.25%. Given that Mustang Bio has higher upside potential than Fortress Biotech, analysts believe Mustang Bio is more attractive than Fortress Biotech.

Fortress Biotech has a beta of 1.825, which suggesting that the stock is 82.547% more volatile than S&P 500. In comparison Mustang Bio has a beta of 2.143, suggesting its more volatile than the S&P 500 by 114.262%.

Fortress Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mustang Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fortress Biotech pays -10.24% of its earnings as a dividend. Mustang Bio pays out -- of its earnings as a dividend.

Fortress Biotech quarterly revenues are $14.6M, which are larger than Mustang Bio quarterly revenues of --. Fortress Biotech's net income of -$12.9M is lower than Mustang Bio's net income of -$1.4M. Notably, Fortress Biotech's price-to-earnings ratio is -- while Mustang Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fortress Biotech is 0.41x versus -- for Mustang Bio. Usually stocks with elevated PS ratios are considered overvalued.